Ingavirin,

Phase 3Small molecule

VValenta Pharm JSC

Ingavirin, is one of 41 small molecule programs targeting COVID-19. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

InfluenzaActive, not recruiting

COVID-19Phase 3

Active, not recruiting

InfluenzaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Ingavirin,

VValenta Pharm JSC

Phase 3

1 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 4

Nitrostat

VViatris Specialty LLC

Preclinical

1 5

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 6

Achromycin V

WWyeth-Lederle Vaccines

Orap

1 8

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 9

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

3 10

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Influenza

NCT07420985

Clinical

Trials by Indication[1]

Influenza2 trials

Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections

Completed·VValenta Pharm JSC·Phase 3·NCT05269290·240 enrolled

Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.

Recruiting·VValenta Pharm JSC·Phase 2·NCT07420985·300 enrolled

COVID-191 trial

Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19

Completed·VValenta Pharm JSC·Phase 3·NCT05216497·233 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Ingavirin,. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ingavirin, compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ingavirin,. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Valenta Pharm JSC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VValenta Pharm JSC

Ingavirin,

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Influenza2 trials

COVID-191 trial

References

Drug Info

Quick Facts

Related News